Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Mood stabilizers inhibit cytomegalovirus infection.

Ornaghi S, Davis JN, Gorres KL, Miller G, Paidas MJ, van den Pol AN.

Virology. 2016 Dec;499:121-135. doi: 10.1016/j.virol.2016.09.012. Epub 2016 Sep 19.

PMID:
27657833
2.

HIV-1 Vpr reactivates latent HIV-1 provirus by inducing depletion of class I HDACs on chromatin.

Romani B, Kamali Jamil R, Hamidi-Fard M, Rahimi P, Momen SB, Aghasadeghi MR, Allahbakhshi E.

Sci Rep. 2016 Aug 23;6:31924. doi: 10.1038/srep31924.

3.

Temporal transcriptional response to latency reversing agents identifies specific factors regulating HIV-1 viral transcriptional switch.

Venkatachari NJ, Zerbato JM, Jain S, Mancini AE, Chattopadhyay A, Sluis-Cremer N, Bar-Joseph Z, Ayyavoo V.

Retrovirology. 2015 Oct 6;12:85. doi: 10.1186/s12977-015-0211-3.

4.

Dose-responsive gene expression in suberoylanilide hydroxamic acid-treated resting CD4+ T cells.

Reardon B, Beliakova-Bethell N, Spina CA, Singhania A, Margolis DM, Richman DR, Woelk CH.

AIDS. 2015 Nov;29(17):2235-44. doi: 10.1097/QAD.0000000000000839.

5.

Progress and challenges in the use of latent HIV-1 reactivating agents.

Shang HT, Ding JW, Yu SY, Wu T, Zhang QL, Liang FJ.

Acta Pharmacol Sin. 2015 Aug;36(8):908-16. doi: 10.1038/aps.2015.22. Epub 2015 Jun 1. Review.

6.

Genome editing strategies: potential tools for eradicating HIV-1/AIDS.

Khalili K, Kaminski R, Gordon J, Cosentino L, Hu W.

J Neurovirol. 2015 Jun;21(3):310-21. doi: 10.1007/s13365-014-0308-9. Epub 2015 Feb 26. Review.

7.

Designed transcription activator-like effector proteins efficiently induced the expression of latent HIV-1 in latently infected cells.

Wang X, Wang P, Fu Z, Ji H, Qu X, Zeng H, Zhu X, Deng J, Lu P, Zha S, Song Z, Zhu H.

AIDS Res Hum Retroviruses. 2015 Jan;31(1):98-106. doi: 10.1089/AID.2014.0121.

8.

HIV-1 latency in monocytes/macrophages.

Kumar A, Abbas W, Herbein G.

Viruses. 2014 Apr 22;6(4):1837-60. doi: 10.3390/v6041837. Review.

9.

Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.

Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, Hesselgesser J, Irrinki A, Murry JP, Stepan G, Stray KM, Tsai A, Yu H, Spindler J, Kearney M, Spina CA, McMahon D, Lalezari J, Sloan D, Mellors J, Geleziunas R, Cihlar T.

PLoS Pathog. 2014 Apr 10;10(4):e1004071. doi: 10.1371/journal.ppat.1004071. eCollection 2014 Apr.

10.

Measuring turnover of SIV DNA in resting CD4+ T cells using pyrosequencing: implications for the timing of HIV eradication therapies.

Reece JC, Martyushev A, Petravic J, Grimm A, Gooneratne S, Amaresena T, De Rose R, Loh L, Davenport MP, Kent SJ.

PLoS One. 2014 Apr 7;9(4):e93330. doi: 10.1371/journal.pone.0093330. eCollection 2014.

11.

Is cure of HIV infection in sight?

Shete A, Paranjape RS.

Indian J Med Res. 2013 Dec;138(6):824-8. No abstract available.

12.

Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing.

Suzuki K, Hattori S, Marks K, Ahlenstiel C, Maeda Y, Ishida T, Millington M, Boyd M, Symonds G, Cooper DA, Okada S, Kelleher AD.

Mol Ther Nucleic Acids. 2013 Dec 3;2:e137. doi: 10.1038/mtna.2013.64.

13.

An upstream YY1 binding site on the HIV-1 LTR contributes to latent infection.

Bernhard W, Barreto K, Raithatha S, Sadowski I.

PLoS One. 2013 Oct 8;8(10):e77052. doi: 10.1371/journal.pone.0077052. eCollection 2013.

14.

Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells.

Shan L, Xing S, Yang HC, Zhang H, Margolick JB, Siliciano RF.

J Antimicrob Chemother. 2014 Jan;69(1):28-33. doi: 10.1093/jac/dkt338. Epub 2013 Sep 1.

15.

HIV-1 transcription and latency: an update.

Van Lint C, Bouchat S, Marcello A.

Retrovirology. 2013 Jun 26;10:67. doi: 10.1186/1742-4690-10-67. Review.

16.

Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials.

Rasmussen TA, Tolstrup M, Winckelmann A, Østergaard L, Søgaard OS.

Hum Vaccin Immunother. 2013 Apr;9(4):790-9. doi: 10.4161/hv.23202. Epub 2013 Apr 1. Review.

17.

Passport control for foreign integrated DNAs: An unexpected checkpoint by class II HDAC4 revealed by amino acid starvation.

Palmisano I, Della Chiara G, Schiaffino MV, Poli G.

Mob Genet Elements. 2012 Sep 1;2(5):233-238.

18.

Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.

Rasmussen TA, Schmeltz Søgaard O, Brinkmann C, Wightman F, Lewin SR, Melchjorsen J, Dinarello C, Østergaard L, Tolstrup M.

Hum Vaccin Immunother. 2013 May;9(5):993-1001. doi: 10.4161/hv.23800. Epub 2013 Jan 31.

19.

Targeting IκB proteins for HIV latency activation: the role of individual IκB and NF-κB proteins.

Fernandez G, Zaikos TD, Khan SZ, Jacobi AM, Behlke MA, Zeichner SL.

J Virol. 2013 Apr;87(7):3966-78. doi: 10.1128/JVI.03251-12. Epub 2013 Jan 30.

20.

Targeting HIV latency: pharmacologic strategies toward eradication.

Xing S, Siliciano RF.

Drug Discov Today. 2013 Jun;18(11-12):541-51. doi: 10.1016/j.drudis.2012.12.008. Epub 2012 Dec 25. Review.

Supplemental Content

Support Center